2型糖尿病心血管并发症发病机制的研究进展

doi:10.16352/j.issn.1001-6325.2022.05.008

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (5): 814-817.doi: 10.16352/j.issn.1001-6325.2022.05.008

2型糖尿病心血管并发症发病机制的研究进展

郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉^*

哈尔滨医科大学附属第一医院内分泌科, 黑龙江哈尔滨 150001

收稿日期:2020-11-16 修回日期:2021-04-30 出版日期:2022-05-05 发布日期:2022-04-28
通讯作者: * xiaorongzhan@sina.com
基金资助:
中国医学科学院生物物理研究所科研基金(KJZD-EW-TZ-L05)

Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus

ZHENG Tian-sheng, TONG Xue-wei, ZHANG Yi-tong, ZHU Min, ZHAN Xiao-rong^*

Department of Endocrinology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Received:2020-11-16 Revised:2021-04-30 Online:2022-05-05 Published:2022-04-28
Contact: * xiaorongzhan@sina.com

摘要/Abstract

摘要： 2型糖尿病(T2DM)患者容易出现多种心血管并发症,如冠状动脉粥样硬化性心脏病、高血压、心力衰竭。导致T2DM患者并发心血管疾病的原因和机制错综复杂。有关的机制包括持续性高血糖、胰岛素抵抗、代谢紊乱、氧化应激、心肌纤维化、小血管病变和心脏自主神经病变。

关键词: 2型糖尿病, 心血管并发症, 胰岛素抵抗

Abstract: Patients with type 2 diabetes mellitus(T2DM) trend toward the multiple cardiovascular complications like coronary atherosclerotic heart disease, hypertension, heart failure. The causes and mechanisms leading to cardiovascular disease in patients with type 2 diabetes mellitus are complicated, which include persistent hyperglycemia, insulin resistance, metabolic disorders, oxidative stress, myocardial fibrosis, small vessel disease and cardiac autonomic neuropathy.

Key words: type 2 diabetes mellitus, cardiovascular complications, insulin resistance

中图分类号:

R587

郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.

ZHENG Tian-sheng, TONG Xue-wei, ZHANG Yi-tong, ZHU Min, ZHAN Xiao-rong. Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus[J]. Basic & Clinical Medicine, 2022, 42(5): 814-817.

参考文献

[1] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50.
[2] American Diabetes Association.10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43:S111-S134.
[3] Braunwald E.Diabetes, heart failure, and renal dysfunction: the vicious circles[J]. Prog Cardiovasc Dis,2019,62:298-302.
[4] Ioachimescu AG. Diabetes and atherosclerotic cardiovascular disease[J]. Endocrinol Metab Clin North Am, 2018,47:xiii-xiv.doi:10.1016/j.ecl.2017.12.002.
[5] Lee SH, Hwang SM, Kang DH, et al. Brain education-based meditation for patients with hypertension and/or type 2 diabetes: a pilot randomized controlled trial[J]. Medicine, 2019, 98:e15574. doi:10.1097/MD.0000000000015574.
[6] Henning RJ.Type-2 diabetes mellitus and cardiovascular disease[J]. Future Cardiol, 2018, 14:491-509.
[7] Connor T, Martin SD, Howlett KF, et al. Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess?[J]. Clin Exp Pharmacol Physiol, 2015, 42:109-115.
[8] Julia R, Rong T. Metabolism in cardiomyopathy: every substrate matters[J]. Cardiovasc Res, 2017,113:411-421.
[9] Kozakova M, Morizzo C, Fraser AG, et al.Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus[J]. Cardiovasc Diabetol, 2017,16:78. doi: 10.1186/s12933-017-0557-z.
[10] Vergès B. Is reduction of hyperglycemia associated with a cardiovascular benefit?[J]. Presse Med, 2018,47:764-768.
[11] Kulkarni H, Mamtani M, Blangero J, et al. Lipidomics in the study of hypertension in metabolic syndrome[J]. Curr Hypertens Rep, 2017, 19:7. doi:10.1007/s11906-017-0705-6.
[12] Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese[J]. Hypertens Res, 2017,40:795-806.
[13] Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation[J]. Cardiovasc Diabetol, 2018, 17:57.doi: 10.1186/s12933-018-0703-2.
[14] Wang HH, Lee DK, Liu M, et al. Novel insights into the pathogenesis and management of the metabolic syndrome[J]. Pediatr Gastroenterol Hepatol Nutr, 2020,23:189-230.
[15] Athithan L, Gulsin GS, Mccann GP, et al. Diabetic cardiomyopathy: pathophysiology, theories and evidence to date[J]. World J Diabetes, 2019,10:490-510.
[16] Dhalla NS, Shah AK, Tappia PS. Role of oxidative stress in metabolic and subcellular abnormalities in diabetic cardiomyopathy[J]. Int J Mol Sci, 2020,21:2413. doi:10.3390/ijms21072413.
[17] Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity[J]. Circ Res, 2018, 122:624-638.
[18] Zhang D, Li Y, Heims-Waldron D, et al. Mitochondrial cardiomyopathy caused by elevated reactive oxygen species and impaired cardiomyocyte proliferation[J]. Circ Res, 2018,122:74-87.
[19] Alonso N, Moliner P, Mauricio D. Pathogenesis, clinical features and treatment of diabetic cardiomyopathy[J]. Adv Exp Med Biol, 2018,1067:197-217.
[20] Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arterioscler Thromb Vasc Biol, 2017, 37:191-204.
[21] Jiewen J, Weimin W, Liangying Z, et al. Cardiovascular autonomic neuropathy is an independent risk factor for left ventricular diastolic dysfunction in patients with type 2 Diabetes[J]. Biomed Res Int, 2017, 2017:3270617. doi:10.1155/2017/3270617.
[22] Ningning W, Asadur R, Hirofumi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity[J]. Front Endocrinol, 2018, 9:421. doi:10.3389/fendo.2018.00421.
[23] Kang S, Verma S, Hassanabad AF, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME Results[J]. Can J Cardiol, 2020,36:543-553.
[24] Verma S, Rawat S, Ho KL, et al. Empaglifiozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors[J].JACC Basic Transl Sci, 2018,3:575-587.
[25] Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action[J]. JAMA Cardiol, 2017,2:1025-1029.
[26] Baartscheer A, Schumacher CA, Wust RC, et al. Empaglifiozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J].Diabetologia, 2017,60:568-573.

2型糖尿病心血管并发症发病机制的研究进展

Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	齐梦亚, 李玉秀, 余洁, 张化冰, 许翎岭, 李伟, 平凡. 新确诊糖尿病患者增加运动与降低胰岛素抵抗和心血管危险因素相关[J]. 基础医学与临床, 2024, 44(7): 984-988.
[2]	舒玲, 霍本念, 宋林. NT5C2在疾病及治疗中的研究进展[J]. 基础医学与临床, 2023, 43(5): 852-856.
[3]	章远谋, 韩康, 夏瑞, 孙文健, 任晓莹, 王砚. 亚临床甲状腺功能减退症对多囊卵巢综合征患者内分泌代谢特征的影响[J]. 基础医学与临床, 2023, 43(4): 641-646.
[4]	赵茂宇, 李佑美, 刘焕云, 毛琦. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1302-1305.
[5]	许晓双, 闵行, 叶月, 郭梦然, 甄东户. 碘与代谢综合征相关性的研究进展[J]. 基础医学与临床, 2022, 42(6): 979-982.
[6]	郑杨, 魏海军, 申嘉陵, 刘润禹, 刘勇, 孙晓磊. MVBs及IL-1β在2型糖尿病大鼠血管钙化中的作用[J]. 基础医学与临床, 2022, 42(2): 208-214.
[7]	张蓝月, 张学东. 分泌蛋白Metrnl在不同疾病中作用的研究进展[J]. 基础医学与临床, 2022, 42(11): 1767-1770.
[8]	孙明玥, 李旭妍, 萨如拉, 李晶晶, 梁浩, 闫朝丽, 苏燕. 2型糖尿病患者红细胞变形能力改变与RBC能量代谢相关[J]. 基础医学与临床, 2021, 41(2): 245-249.
[9]	杨静, 李民. SIRT3介导的线粒体功能和代谢调控机制在2型糖尿病中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1828-1832.
[10]	孙影, 董世云. 妊娠期代谢综合征对母亲健康及后代生长发育影响的研究进展[J]. 基础医学与临床, 2021, 41(10): 1518-1522.
[11]	刘宁, 张伟华. 糖尿病合并高血压加重血管病变的研究进展[J]. 基础医学与临床, 2020, 40(7): 990-994.
[12]	卢亚男, 刘丽俊, 李伟. GA/HbA1c比值与2型糖尿病合并非酒精性脂肪肝相关[J]. 基础医学与临床, 2020, 40(12): 1636-1639.
[13]	郭宝璐, 白涛, 郭杰, 刘萌萌, 杨彩红, 章毅, 范彦英. 基于RNA-seq的db/db小鼠大脑皮质的转录组学分析[J]. 基础医学与临床, 2020, 40(1): 16-23.
[14]	杨波熊婉媛铁宝霞蔡小玲哈小琴. 糖尿病与细胞焦亡[J]. 基础医学与临床, 2019, 39(7): 1061-1065.
[15]	朱伟郑世霞柯琳秋汪毅陈琼科夏道涵王红漫. SFRP5基因对小鼠肝癌细胞Hepa1-6糖代谢的影响[J]. 基础医学与临床, 2018, 38(9): 1268-1273.